CV Sciences, Inc. reported a decline in financial performance for the fiscal year ending December 31, 2025, with net product sales totaling $13.8 million, a decrease of 12.2% from $15.7 million in 2024. The company's gross profit also fell to $6.8 million, down from $7.2 million the previous year, although gross margins improved to 49.0% from 45.6%. The decrease in revenue was attributed to lower sales volume, with a 12.6% reduction in the total number of units sold, partially offset by a slight increase in average sales price per unit. Notably, 39% of the revenue came from new products launched since January 2023, indicating ongoing efforts to innovate within a competitive market.
In terms of strategic developments, CV Sciences made significant acquisitions, including the purchase of Cultured Foods, a European manufacturer of plant-based protein products, in December 2023, and Elevated Softgels, a manufacturer of encapsulated softgels, in May 2024. The company also launched a new brand, Lunar Fox, in January 2025, focusing on plant-based products in the U.S. market. These acquisitions and product launches are part of the company's strategy to diversify its offerings and enhance its market presence.
Operationally, CV Sciences reported a reduction in employee headcount, with 44 employees as of December 31, 2025, down from 49 in the previous year. The company sold products through approximately 2,500 brick-and-mortar stores and emphasized its commitment to e-commerce, which has become increasingly important in the consumer goods sector. The company’s plant-based food products are primarily distributed in Europe, where the market is growing, while its hemp-based products are mainly sold in North America.
The filing also highlighted challenges posed by regulatory changes, particularly the November 2025 Appropriations Act, which will impose stricter limits on THC levels in hemp-derived products starting November 2026. This legislation could significantly impact CV Sciences' product portfolio and operations. The company is currently evaluating the potential effects of this legislation and is preparing to adjust its product formulations and compliance measures accordingly.
Looking ahead, CV Sciences aims to continue innovating and expanding its product lines while navigating a competitive landscape marked by regulatory uncertainty. The company plans to focus on cost reductions and operational efficiencies to improve its financial position, although it acknowledges the need for additional capital to support its growth initiatives. The management remains cautious about the future, given the evolving market conditions and regulatory environment that could affect its business operations.
About CV Sciences, Inc.
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals, hemp extracts, and plant-based foods. Its core brands include +PlusCBD® for hemp-derived CBD products and Cultured Foods and Lunar Fox for plant-based foods. The company serves retail and online markets in the U.S. and Europe, emphasizing science-backed, high-quality products, with a focus on innovation, regulatory compliance, and strategic acquisitions in the health and food sectors.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.